GBT Guerbet SA

GUERBET : Implementation of a Liquidity Contract with NATIXIS ODDO BHF

GUERBET : Implementation of a Liquidity Contract with NATIXIS ODDO BHF

Implementation of a Liquidity Contract with NATIXIS ODDO BHF

Villepinte, 3 February 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, ends its liquidity contract ongoing since 9 March 2022 and announces having appointed NATIXIS and ODDO BHF to implement a liquidity contract, starting on 3 February 2025, for a period of one year tacitly renewable.

This contract complies with the decision of the Autorité des marchés financiers (AMF) n°2021-01 of June, 22 2021 related to the establishing of liquidity contracts on shares as accepted market practice and the standard contract of the Association française des marchés financiers (AMAFI).

This contract with NATIXIS ODDO BHF aims at improving Company’s shares trading on the regulated market of Euronext Paris

Before the termination, the following resources were allocated to the liquidity account:

  • 10 996 shares
  • 340 083.86 euros

The following resources have been allocated to the liquidity account:

  • 10 996 shares
  • 340 083.86 euros

The execution of the liquidity contract may be suspended upon occurrence of the following events or conditions:

  • when all conditions provided in Article 5 of the AMF Decision n°2021-01 June 22, 2021 are met;
  • if the share is listed outside the thresholds authorized by the Company’s Shareholders’ Meeting;
  • upon the Company request.



The liquidity contract may be terminated at any time and without prior notice by GUERBET, at any time by NATIXIS and/or ODDO BHF SCA subject to fifteen (15) calendar days' notice

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023.

Contacts:

Guerbet

Jérôme Estampes, Chief Financial Officer 00 /

Christine Allard, Head of Public Affairs and Communications: 82 / 



Seitosei.Actifin

Marianne Py, Financial Communication 31 /

Jennifer Jullia, Press 19 /



Attachment



EN
03/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Guerbet SA

 PRESS RELEASE

GUERBET : Nombre d'actions et de droits de vote composant le capital d...

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2025 GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2025 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les sociétés dont des actions sont admises aux négociations sur un marché réglementé publient sur leur site Internet et transmettent à l'AMF, à la fin de chaque mois, le nombre total de droits de vote et le nombre d'actions composant le capital de la société s'ils ont varié p...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

GUERBET: Chiffre d’affaires du 1er trimestre 2025

GUERBET: Chiffre d’affaires du 1er trimestre 2025 Chiffre d’affaires du 1er trimestre 2025 Activité trimestrielle Chiffre d’affaires : 180,1 M€, en repli de 7,1% à TCC1 et périmètre comparable2Comme anticipé, un premier trimestre marqué par un impact France persistant et un effet de base pénalisantUne dynamique en retrait en Imagerie Diagnostique (-8,7% à TCC et périmètre comparable) et en croissance en Imagerie Interventionnelle (+5,8% à TCC et périmètre comparable) Confirmation des objectifs annuels Nouvelle progression de la rentabilité : taux de marge d’EBITDA retraité3 attendu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch